Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers

Abstract Aims  Phospholamban (PLN) p.Arg14del mutation carriers are at risk of developing malignant ventricular arrhythmias (VAs) and/or heart failure. Currently, left ventricular ejection fraction (LVEF) plays an important role in risk assessment for VA in these individuals. We aimed to study the incremental prognostic value of left ventricular mechanical dispersion (LVMD) by echocardiographic deformation imaging for prediction of sustained VA in PLN p.Arg14del mutation carriers. Methods and results We included 243 PLN p.Arg14del mutation carriers, which were classified into three groups according to the ‘45/45’ rule: (i) normal left ventricular (LV) function, defined as preserved LVEF ≥45% with normal LVMD ≤45 ms (n = 139), (ii) mechanical LV dysfunction, defined as preserved LVEF ≥45% with abnormal LVMD >45 ms (n = 63), and (iii) overt LV dysfunction, defined as reduced LVEF <45% (n = 41). During a median follow-up of 3.3 (interquartile range 1.8–6.0) years, sustained VA occurred in 35 individuals. The negative predictive value of having normal LV function at baseline was 99% [95% confidence interval (CI): 92–100%] for developing sustained VA. The positive predictive value of mechanical LV dysfunction was 20% (95% CI: 15–27%). Mechanical LV dysfunction was an independent predictor of sustained VA in multivariable analysis [hazard ratio adjusted for VA history: 20.48 (95% CI: 2.57–162.84)]. Conclusion  LVMD has incremental prognostic value on top of LVEF in PLN p.Arg14del mutation carriers, particularly in those with preserved LVEF. The ‘45/45’ rule is a practical approach to echocardiographic risk stratification in this challenging group of patients. This approach may also have added value in other diseases where LVEF deterioration is a relative late marker of myocardial dysfunction.

[1]  A. Wilde,et al.  Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of Symptoms. , 2020, JACC. Cardiovascular imaging.

[2]  F. Zannad,et al.  Left ventricular myocardial deformation pattern, mechanical dispersion, and their relation with electrocardiogram markers in the large population-based STANISLAS cohort: insights into electromechanical coupling. , 2020, European heart journal cardiovascular Imaging.

[3]  F. Asselbergs,et al.  Evaluation of Disease Progression in Arrhythmogenic Cardiomyopathy: The Change of Echocardiographic Deformation Characteristics Over Time. , 2020, JACC. Cardiovascular imaging.

[4]  T. Edvardsen,et al.  Prediction of Ventricular Arrhythmias With Left Ventricular Mechanical Dispersion: A Systematic Review and Meta-Analysis. , 2020, JACC. Cardiovascular imaging.

[5]  Y. Pinto,et al.  Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. , 2019, European heart journal cardiovascular Imaging.

[6]  R. Hauer,et al.  The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update , 2019, Netherlands Heart Journal.

[7]  B. Gerber,et al.  Myocardial strain imaging: review of general principles, validation, and sources of discrepancies , 2019, European heart journal cardiovascular Imaging.

[8]  Karim Taha,et al.  The Prognostic Value of Right Ventricular Deformation Imaging in Early Arrhythmogenic Right Ventricular Cardiomyopathy. , 2019, JACC. Cardiovascular imaging.

[9]  R. N. Planken,et al.  Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging , 2019, European heart journal cardiovascular Imaging.

[10]  R. D. de Boer,et al.  Prevalence and cardiac phenotype of patients with a phospholamban mutation , 2018, Netherlands Heart Journal.

[11]  Thor Edvardsen,et al.  Prediction of Life-Threatening Ventricular Arrhythmia in Patients With Arrhythmogenic Cardiomyopathy: A Primary Prevention Cohort Study. , 2018, JACC. Cardiovascular imaging.

[12]  S. Heymans,et al.  Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. , 2016, European heart journal.

[13]  Maja Cikes,et al.  Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. , 2016, European heart journal.

[14]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[15]  G. Pedrizzetti,et al.  Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[16]  R. Hauer,et al.  Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. , 2015, European heart journal.

[17]  R. Hauer,et al.  Outcome in Phospholamban R14del Carriers: Results of a Large Multicentre Cohort Study , 2014, Circulation. Cardiovascular genetics.

[18]  J. G. Post,et al.  Recurrent and founder mutations in the Netherlands—Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy , 2013, Netherlands Heart Journal.

[19]  R. Hauer,et al.  Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy , 2012, European journal of heart failure.

[20]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, European heart journal.

[21]  R. Hetzer,et al.  Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. , 2009, Heart Rhythm.

[22]  Kristina Hermann Haugaa,et al.  Left ventricular mechanical dispersion by tissue Doppler imaging: a novel approach for identifying high-risk individuals with long QT syndrome , 2008, European heart journal.

[23]  Pieter A Doevendans,et al.  Cardiovascular Ultrasound BioMed Central Review , 2006 .

[24]  B. Soliven,et al.  Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[25]  G. Dorn,et al.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[27]  J. Pernod,et al.  [Assessment of left ventricular function by echocardiography]. , 1976, Coeur et medecine interne.